pharma
Reckitt Benckiser to unveil £105 R&D site in Hull by end of June
April 11, 2019Manufacturing and Production Hull, R&D, Reckitt Benckiser, UK, pharma
Reckitt Benckiser (RB) has announced that its £105 million research and development facility in the UK city of Hull – …
Novartis’ Kisqali combo rejected by NICE for advanced breast cancer
April 11, 2019Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma
Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, …
FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients
April 10, 2019Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …
Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer
April 10, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma
Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …
Pharmacy Benefit Manager (PBM) execs testify before US Senate
April 10, 2019Research and Development PBMs, Rebates, Senate, US, pharma, senator, sfc
Executives representing pharmacy benefit managers (PBMs) appeared before the US Senate Finance Committee on Tuesday as they testified on the …
Epilepsy Society calls for review of UK supply chain following “steep rise” in access issues
April 9, 2019Manufacturing and Production, Sales and Marketing Epilepsy Society, UK, brexit, epilepsy, market access, pharma
The Epilepsy Society has drawn attention to the “steep rise” in UK patients who are encountering difficulty in accessing seizure …
United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure
April 9, 2019Manufacturing and Production, Research and Development Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertension
United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its …
ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1
April 9, 2019Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma
ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …
Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer
April 8, 2019Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma
Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …
Kymab announces Merck exec Simon Sturge as new CEO
April 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, appointment, kymab, pharma
UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins …
Protecting public health: Is real-world evidence the key?
April 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, real world data, real world evidence, real-world data, real-world evidence
In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need …
NICE turns down Astellas’ Xtandi in prostate cancer
April 8, 2019Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer
Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …
Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership
April 8, 2019Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease
Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …
Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds
April 8, 2019Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data
A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …
Merrimack shuts down development of investigational cancer drug, staff cuts to follow
April 8, 2019Research and Development, Sales and Marketing cacner, merrimack, oncology, pharma
Merrimack Pharmaceuticals has taken the decision to terminate development of its antibody-directed nanotherapeutic cancer therapy MM-310 in the treatment of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
